Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 7/3067% above fair value
$3.45−0.07 (-1.99%)
Close on Nov 13, 2026Market cap $275.32MP/E –Yield –
Earnings
Prelude Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 11, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.14
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Prelude Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 11, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | -$0.14 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 10, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $6.50M | – | -$0.26 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025during market hours | – | – | -$0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024before the open | – | – | -$0.46 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | – | – | -$0.42 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023during market hours | – | – | -$0.45 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | – | – | -$0.54 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023before the open | – | – | -$0.58 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 15, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | -$0.63 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | – | – | -$0.58 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | – | – | -$0.63 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 16, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | – | – | -$0.66 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 16, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Prelude Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Prelude Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Prelude Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- News
- Update
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Update
See a number that looks wrong?